Loading...
XHKG
1951
Market cap691mUSD
Jul 09, Last price  
2.04HKD
1D
-1.92%
1Q
-17.41%
IPO
-76.66%
Name

Jinxin Fertility Group Ltd

Chart & Performance

D1W1MN
XHKG:1951 chart
P/E
P/S
1.82
EPS
Div Yield, %
2.92%
Shrs. gr., 5y
2.57%
Rev. gr., 5y
12.59%
Revenues
2.58b
-8.22%
346,408,000662,774,000921,994,0001,648,496,0001,426,088,0001,838,826,0002,364,479,0002,788,910,0002,811,596,0002,580,512,054
Net income
-951m
L
87,584,00098,783,000166,600,000409,623,000251,622,000339,901,000121,124,000344,723,000283,099,000-950,882,259
CFO
476m
-24.36%
108,982,00047,682,000356,437,000452,568,000308,039,000343,452,000541,740,000684,484,000629,201,000475,936,955
Dividend
Jun 29, 20260.0418 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company primarily focused on delivering assisted reproductive services (ARS) across both China and the United States. The company offers a comprehensive range of fertility treatments, encompassing artificial insemination, which can be performed using either a husband's or donor sperm, and advanced in vitro fertilization (IVF) techniques such as conventional IVF with embryo transfer or IVF enhanced by intracytoplasmic sperm injection (ICSI). Supporting these core services, Jinxin also provides patients with nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, its operations extend to general medical services including gynecology, urology, and internal medicine, along with managing outpatient surgical facilities and various ancillary medical provisions. The group also conducts pre-implantation genetic screening tests and engages in diverse ventures like investment management, management consultancy, and real estate development and operation.
IPO date
Jun 25, 2019
Employees
3,045
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT